|
|
VANCOUVER, BC / ACCESSWIRE / May 1, 2024 / MindBio Therapeutics Corp. CSE:MBIOFrankfurt:WF6, the "Company" or "MindBio", is pleased to announce that it has been presenting MindBio to various parties, institutional investment firms and brokerage firms for a potential dual listing on a senior exchange in the United States or Australia.The Company has successfully completed P... Lire le communiqué |
|
|
|
| |
|
| |
|
|
VANCOUVER, BC / ACCESSWIRE / May 2, 2024 / MindBio Therapeutics Corp. CSE:MBIOFrankfurt:WF6, the "Company" or "MindBio", a clinical stage biopharma company pioneering microdosing treatments for mental health conditions showcases Dr Rachael Sumner, presenting MindBios landmark womens health trials.... Lire le communiqué |
|
|
|
| |
|
| |
|
|
VANCOUVER, BC / ACCESSWIRE / May 2, 2024 / MindBio Therapeutics Corp. CSE:MBIOFrankfurt:WF6, the "Company" or "MindBio", a clinical stage biopharma company pioneering microdosing treatments for mental health conditions showcases Dr Rachael Sumner, presenting MindBios landmark womens health trials.... Lire le communiqué |
|
|
|
| |
|
| |
|
|
VANCOUVER, BC / ACCESSWIRE / May 1, 2024 / MindBio Therapeutics Corp. CSE:MBIOFrankfurt:WF6, the "Company" or "MindBio", is pleased to announce that it has been presenting MindBio to various parties, institutional investment firms and brokerage firms for a potential dual listing on a senior exchange in the United States or Australia.The Company has successfully completed P... Lire le communiqué |
|
|
|
| |
|
| |
|
|
ASSESSING THE EFECTS OF MICRODOSING MB22001 IN MENSTRUATING PERSONS WITH AND WITHOUT PREMENSTRUAL SYNDROME AND PREMENSTRUAL DYSPHORIC DISORDER Multiple clinical trials in women's health approved for takehome use of MB22001MB22001 aims to address huge unmet need in the 25% of women experiencing PMS symptomsMB22001 to be used acutely to address the mood sensitive phases of the me... Lire le communiqué |
|
|
|
| |
|
| |
|
|
ASSESSING THE EFECTS OF MICRODOSING MB22001 IN MENSTRUATING PERSONS WITH AND WITHOUT PREMENSTRUAL SYNDROME AND PREMENSTRUAL DYSPHORIC DISORDER Multiple clinical trials in women's health approved for takehome use of MB22001MB22001 aims to address huge unmet need in the 25% of women experiencing PMS symptomsMB22001 to be used acutely to address the mood sensitive phases of the me... Lire le communiqué |
|
|
|
| |
|
| |
|
|
MindBio scientist's sleep research published in prestigious peer reviewed scientific journalMindBio's proprietary treatment protocol using MB22001, results in longer sleep and better quality of sleep the day after microdosing VANCOUVER, BC / ACCESSWIRE / April 23, 2024 / MindBio Therapeutics Corp. CSE:MBIOFrankfurt:WF6,... Lire le communiqué |
|
|
|
| |
|
| |
